LifeMD (LFMD) EBITDA (2012 - 2025)

LifeMD's EBITDA history runs 14 years deep, the most recent figure standing at -$6.2 million for Q4 2025.

• Quarterly EBITDA fell 4.26% year-over-year to -$6.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.1 million (up 81.55% YoY) and the FY2025 annual result came in at -$7.7 million, up 62.41% from the prior year.
• EBITDA was -$6.2 million for Q4 2025 at LifeMD, down from -$2.0 million in the prior quarter.
• Across five years, EBITDA topped out at $2.2 million in Q1 2025 and bottomed at -$16.1 million in Q2 2021.
• A 5-year average of -$6.9 million and a median of -$6.2 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2021 — EBITDA slumped 584.76% — and 2025, when it soared 134.94%.
• LifeMD's EBITDA stood at -$13.7 million in 2021, then rose by 24.1% to -$10.4 million in 2022, then surged by 79.06% to -$2.2 million in 2023, then sank by 174.87% to -$6.0 million in 2024, then retreated by 4.26% to -$6.2 million in 2025.
• Business Quant data shows LFMD's EBITDA at -$6.2 million in Q4 2025, -$2.0 million in Q3 2025, and $1.9 million in Q2 2025.